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Abstract
PDE7 inhibitors regulate pro-inflammatory and immune T-cell functions, and are a potentially novel
class of drugs especially useful in the treatment of a wide variety of immune and inflammatory
disorders. Starting from our lead family of thioxoquinazolines, we designed, synthesized, and
characterized a novel series of thioxoquinazoline derivatives. Many of these compounds showed
inhibitory potencies at sub-micromolar levels against the catalytic domain of PDE7A1 and at the
micromolar level against PDE4D2. Cell-based studies showed that these compounds not only
increased intracellular cAMP levels, but also had interesting anti-inflammatory properties within a
therapeutic window. The in silico data predict that these compounds are capable of the crossing the
blood–brain barrier. The X-ray crystal structure of the PDE7A1 catalytic domain in complex with
compound 15 at a resolution of 2.4 Å demonstrated that hydrophobic interactions at the active site
pocket are a key feature. This structure, together with molecular modeling, provides insight into the
selectivity of the PDE inhibitors and a template for the discovery of new PDE7 or PDE7/PDE4 dual
inhibitors.
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Introduction
Phosphodiesterases (PDEs) are a large family of metallophos-phohydrolase enzymes that
ubiquitously metabolize the second messengers adenosine and guanosine 3′,5′-cyclic
monophosphates (cAMP and cGMP) to their respective inactive 5′-monophosphates.[1] cAMP
and cGMP are synthesized by adenylyl and guanylyl cyclases respectively, and mediate the
action of hormones, neurotransmitters, and other cellular effectors in many physiologic
processes. As elevation of intracellular cAMP level impacts immunosuppressive and anti-
inflammatory properties,[2,3] selective inhibitors of cAMP-specific PDEs have been widely
studied as therapeutics for the treatment of human diseases,[4] predominantly immune
disorders such as multiple sclerosis[5] and inflammatory processes,[6] and also disorders of
the central nervous system (CNS) such as depression, psychosis, and Alzheimer’s disease.[7]
PDE families 3B, 4A, 4B, 4D, and 7A1 are predominant in immune cells.[8–10] To date, most
of the research has been centered on PDE4 inhibitors because PDE4 represents the major
isoenzyme in most T-cell preparations and its selective inhibitors are able to decrease
inflammatory cytokine production.[10,11] PDE4 inhibitors have been widely studied as anti-
inflammatory agents for the treatment of asthma, COPD (chronic obstructive pulmonary
disease), rheumatoid arthritis, and multiple sclerosis.[12,13] However, a major drawback of
these compounds is the significant side effects such as emesis. To overcome these adverse
effects, several strategies to dissociate the beneficial and detrimental effects of PDE4 inhibitors
have led to some degree of success and the second generation of PDE4 inhibitors have shown
better pharmacokinetic profiles.[14]
An alternative approach is to target other cAMP-specific PDE families that are expressed in
pro-inflammatory and immune cells. Initial evidence indicated that PDE7 had an important
role in the activation of T-cells.[15,16] However, results based on the use of PDE7A knockout
mice (PDE7A−/−) failed to confirm the role of PDE7A in T-cell proliferation and suggested
that this phosphodiesterase could have some other role in the regulation of humoral immune
responses.[17] Thus, selective PDE7A inhibitors would be essential to elucidate the true
potential of PDE7A as a pharmacological target in the context of the immune response.[18]
Benzo- and benzothienothiadiazine derivatives, developed in our laboratory, constituted the
first heterocyclic family of compounds with PDE7 inhibitory properties.[19,20] Since then,
spiroquinazolinones, sulfonamide, thiadiazole, purine, and pyrimidine nucleotide analogues
have been described as PDE7 inhibitors.[21–23]
The advent of selective PDE7 inhibitors has allowed the assessment of the functional roles that
PDE7 plays in cells and tissues. Although inhibition of PDE7A does not attenuate the
proliferation of T-cells per se, it significantly augments the anti-mitogenic and cAMP-elevating
activities of PDE4 inhibitors.[24] Therefore, PDE7 or PDE7/PDE4 dual inhibitors would
represent a novel class of drugs that could regulate pro-inflammatory and immune T-cell
function and be especially useful in treating a wide variety of immune and inflammatory
disorders.[25–27] Such drugs may also have less undesirable side effects, such as nausea and
vomiting.[28]
The latest scientific findings concerning PDE7 and PDE4 inhibition suggest that selective
small-molecule inhibitors of both enzymes could provide a novel approach to treat a variety
of immunological diseases. In this context, ligand-based virtual screening studies allowed us
to identify thiadiazine and quinazoline derivatives as a new class of PDE7 inhibitors.[29] Our
preliminary study revealed that the novel thioxoquinazoline compounds 2–5 were equally
potent to the target structure 1 (Table 1). On the basis of our previous results, this study is
undertaken to explore new modifications on the quinazoline scaffold to better understand their
therapeutic relevance. Reported herein is the chemical synthesis of the proposed molecules
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and their inhibition on PDEs. The crystal structure of PDE7 in complex with a potent inhibitor
is determined by X-ray crystallography and the insight into the design of PDE7 inhibitors is
further illustrated by molecular modeling studies. Cell-based studies were performed to
investigate the effects on intracellular cAMP levels and the anti-inflammatory properties of
the new compounds.
Results and Discussion
Chemistry
The new compounds presented in this study retain the basic skeleton of thioxoquinazoline and
an aryl substituent linked to nitrogen 3, whereas methyl or bromine is introduced in the benzene
fused ring. Methylation of the thiocarbonyl group and/or thionation of the carbonyl group is
performed on the thioxoquinazoline ring or some thieno- and benzothienopyrimidine
compounds reported previously.[29]
To prepare the new quinazoline derivatives 6–13, the condensation between the 2-amino-5-
bromobenzoic acid or 2-amino-3-methylbenzoic acid and the corresponding isothiocyanate
was performed in ethanol at 4°C (Scheme 1). The bromoquinazolines 6–9 were obtained
according to this procedure in high purity by simple filtration of the crude product. However,
a purification step was necessary to obtain methylquinazolines 10–13 after the condensation
step.
To obtain the S-methyl derivatives 14–25, compounds 2–13 were methylated in DMF at room
temperature using methyl iodide and potassium carbonate (Scheme 2).[30] The thionation of
the carbonyl group at position 4 of derivatives 2–25 was tried with Lawesson’s reagent under
reflux in toluene (Scheme 2), but only derivatives 26–32 were obtained.[31,32] Following
similar procedures, it was possible to obtain modified thieno- and benzothienopyrimidine
(Schemes 3 and 4). Thus, the most active thieno- and benzothienopyrimidine derivatives
previously reported 33, 34, and 38[29] were methylated, producing S-methyl derivatives 35,
36, and 39 respectively. Compounds 35 and 39 were further thionated at position 4 yielding
the corresponding thiocarbonyl derivatives 37 and 40 (Schemes 3 and 4, respectively). It should
be mentioned that compound 37 proved to be unstable and decomposed after its structural
elucidation.
The structures of all new compounds were determined by their analytical and spectroscopic
data (1H and 13C NMR), which are described in the Experimental Section or in the Supporting
Information. Unequivocal assignment of all chemical shifts (1H and 13C NMR) was performed
using two-dimensional experiments such as HSQC for one-bond correlation. The site of
substitution was confirmed by the HMBC for long distance proton–carbon correlation.
In vitro evaluation of PDE inhibition
The new derivatives were tested for their inhibitory potencies against the catalytic domain of
PDE7A1 and full-length PDE4D2 as described in the Experimental Section (Table 2). Among
the new heterocyclic compounds, some of them (13–15, 19–21, 23, 25, 26, 29, and 36–39) are
more potent than the previous quinazoline derivatives 2–5.[29] In addition, compounds 15,
19, 23, 25, 29, and 39, also inhibit PDE4, and therefore can be considered as potential PDE7/
PDE4 dual inhibitors for the treatment of T-cell disorders. In addition, the S-methyl derivatives
have better activity than the previously described compounds (IC50 values of 0.51 µM for 15
and 0.13 µM for 23). Strikingly, among the members of this S-methyl family, compounds 18
and 22, which bear a phenyl group at position 3, are less active than 15, 19, 23, and 25, which
are mono- or di-substituted at the ortho position of the benzene ring. The compounds with the
benzene fused ring replaced by a thieno or benzothieno moiety show similar activity.
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Cell viability determined by PI exclusion
To evaluate potential in vivo use of these compounds, cell-based studies were performed. To
this end, we determined the effect of PDE inhibitors 2, 5, 13, 15, 19–23, 25–27, 29, 30, 32,
36, 39, and 40 on T-cell viability by studying propidium iodide (PI) exclusion in the murine
T-cell line D10.G4.1 and subsequent flow cytometry analysis. We used this cell line because
PDE7 is abundantly expressed in murine T-cells[33] and the percentage of identity between
human and murine PDE7 is 90–96 %.[34]
Cells were cultured in the presence of different concentrations of each PDE inhibitor for 48 h
before flow cytometry analysis. Cell viability was quantified as the percentage of PI-
impermeable cells and known selective inhibitors BRL50481 (PDE7) and Rolipram (PDE4)
were used as references. Figure 1 shows dose-dependent effects for almost all the inhibitors,
which are compatible with their inhibition of PDE7A in vitro.
Intracellular cAMP levels
The next step was to check if our compounds were able to regulate intracellular cAMP levels
in the T-cell clone D10.G4.1. PDE4 inhibitor Rolipram is more effective than PDE7 inhibitor
BRL50481 in the induction of intracellular levels of cAMP (Figure 2). Compound 26 was able
to increase cAMP to the same level as those induced by BRL50481. Simultaneous addition of
Rolipram with BRL50481 or inhibitor 26 had a synergistic effect on intracellular cAMP levels.
This result is consistent with the previous report for BRL50481.[24] In fact, the new inhibitor
26 showed an almost identical behavior in increasing the intracellular cAMP level.
Anti-inflammatory effects
To verify our working hypothesis that the inflammatory response could be modulated by cAMP
levels, we next tested the potential anti-inflammatory effects of our new PDE7 inhibitors 13,
15, and 26 in a cell-based model. To this end, lipopolysaccharide (LPS) was used to induce an
inflammatory response in the murine macrophage cell line. The standard reference BRL50481
showed an anti-inflammatory effect as measured by a significant decrease in nitrite production.
The new PDE7 inhibitors showed the same biological behavior and significantly decreased
nitrite production (Figure 3).
Notably, Rolipram decreased nitrite production to the same extent as BRL50481, whereas its
effect in increasing cAMP levels was much more marked. We again found a synergy between
the PDE7 inhibitors and Rolipram, and a dramatic decrease in nitrite levels was detected when
these PDE7 inhibiting compounds or BRL50481 were used in conjunction with Rolipram
(Figure 3). These results confirm that compounds 15, 26, and 13 are good candidates for further
analysis in animal models of inflammatory diseases.
Prediction of BBB permeation
ADME (absorption, distribution, metabolism, and excretion) properties such as the ability to
cross the blood–brain barrier (BBB) are important properties to indicate the usefulness of lead
compounds. Herein, we determined in silico the ability of some of the newly synthesized
compounds to cross the BBB using our CODES-based model.[35] According to the model,
our most promising candidates were able to cross the BBB and could therefore be used as
potential new drugs for the treatment of neurological disorders (table S1 in the Supporting
Information).
Binding mode of PDE7 inhibitors: crystal structure of PDE7A1–compound 15
The crystallographic data on the catalytic domain of PDE7A1 in complex with the nonselective
inhibitor 3-isobutyl-1-methylxanthine (IBMX; PDB code 1ZKL)[36] prompted us to use the
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same methodology to reveal the structural basis for the biological function of the potent
compound 15 (IC50=0.51 µM). The structure of PDE7A1 (residues 130–482) in complex with
15 has the topological folding of PDE7A1–IBMX.[36] The structural superposition of the
PDE7A1–15 and PDE7A1–IBMX complexes yielded a root-mean-square deviation (RMSD)
of 0.18 Å, indicating that the two inhibitor-bound structures are similar. Residues 130–138 and
457–482 were not traceable in the structure because of a lack of electron density. The structure
contains 16 α helices (Figure 4) and has the same folding topology as those of other PDEs.
[37]
The two essential elements for binding of all PDE inhibitors are stacking against a conserved
phenylalanine and the hydrogen bond with an invariant glutamine.[37] In our case, compound
15 binds to the active site of PDE7A1 and forms hydrophobic interactions with residues Ile323,
Ile363, Val380, Phe384, Leu401, Phe416, and Leu420 (Figure 4) and an aromatic interaction
with the conserved Phe416. However, the hydrogen bond with Gln413 is not present in the X-
ray crystal structure of the PDE7A1–15 complex.
As hydrophobic interactions are typically nonspecific, we were curious if compound 15 is also
potent in inhibition of other PDE families. The enzymatic assay showed that compound 15 at
a concentration of 200 µM did not inhibit cGMP-specific PDE5 and PDE9. However, 15
moderately inhibited PDE2A, PDE3A, and PDE10A with IC50 values of 8.2, 65.0, and 11.3
µM, respectively. Thus, 15 showed 16, 127, 6.9, > 392, > 392, and 22-fold selectivity against
PDE2A, PDE3A, PDE4D, PDE5A, PDE9A, and PDE10A, with respect to PDE7A (IC50=0.51
µM).
Theoretical binding studies
Keeping in mind the hydrophobic nature of the interaction of 15 in the binding site of PDE7A1,
the observed selectivity against PDE enzymes is surprising, especially if we take into account
that several residues that define the binding site are distant from the inhibitor (Figure 5 and
Table 3). To gain insight into the molecular determinants responsible for such selectivity,
compound 15 was docked in the binding site of PDE7A1 using the program rDock. This
docking allowed us to reproduce the binding mode that has an RMSD of less than 2 Å from a
series of the observed X-ray crystal structures of PDE4 inhibitors (see Supporting Information).
In addition to the X-ray crystallographic binding mode (mode B), the docking revealed an
alternative pose with a slightly better score (Figure 5; mode A), in which the inhibitor partially
overlapped with the region occupied by mode B, but penetrated deeper into the binding pocket.
Interestingly, this latter binding mode enables the carbonyl oxygen of 15 to form a hydrogen
bond with the side chain NH2 group of Gln413, while the stacking against Phe416 is retained.
Accordingly, this binding mode mimics the basic trends observed for the binding of IBMX to
PDE7. Similar results were found in the docking of the thieno derivative 36 (data not shown).
As docking scoring functions are typically developed to allow a high computational speed in
the virtual screening of a large collection of compounds, they involve a number of
approximations that limit their accuracy in predicting the most favorable docking poses.
Therefore, MM/PBSA (molecular mechanics/ Poisson–Boltzmann surface area), which has
been successfully applied to predict the relative affinities of structurally related ligands,[38–
41] was used to evaluate the relative affinity of the two binding modes of the inhibitor. This
technique combines a rigorous treatment of electrostatics, which includes solvent screening
effects upon complex formation, as well as nonpolar terms for the van der Waals interactions
between inhibitor and receptor, and for the desolvation free energy. For our purposes, this
technique appears to be well suited to discriminate between the different poses of the same
inhibitor in the binding site of PDE7A1.
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Although the choice of the solute dielectric constant affected the absolute values of the
electrostatic components of the binding affinity (Table 4), it has much less impact on the
differences between the two binding modes. The nonpolar contribution to the solvation free
energy is very similar in the two binding modes. In contrast, the van der Waals term shows a
6.4 kcal mol−1 energy difference, favoring the alternative binding mode A over the X-ray-like
binding mode. The preference of this binding mode is counter balanced by the difference in
the internal energy (2.9 kcal mol−1), which reflects the conformational penalty due to
rearrangements of the side chains of residues. Nevertheless, this opposing term is not sufficient
to compensate for the larger energy in the van der Waals interaction between the receptor and
inhibitor in binding mode A.
A feature of particular relevance in the A binding mode is that the difluoro-substituted benzene
ring points toward Ser373, which is one of the often divergent residues in the binding site of
phosphodiesterases (see Figure 5 and Table 3). As Ser373 is replaced by Tyr in PDE4, it is
reasonable to expect that the bulkier size of the PDE4 residue can increase the steric hindrance
with the difluoro-substituted benzene ring and eventually weaken the hydrogen bond with the
glutamine in PDE4. For PDE2 and PDE10, even though Ser373 is replaced by Thr, Pro366 is
mutated to Gln and Val respectively, whose side chains might also affect the positioning of the
difluorobenzene unit of 15 in their binding site. More drastic changes are found in PDE3, PDE5,
and PDE9. Thus, Ser373 and Pro366 are mutated respectively to His and Val in PDE3, Gln
and Ile in PDE5, and Ala and Glu in PDE9. Therefore, altering the shape, size, and electrostatic
features of these residues may contribute to the selective binding of compound 15, and Ser373
may be an important residue for the selectivity of PDE inhibitors.
Overall, it can be speculated that the adoption of binding mode A could follow a two-step
binding mechanism, where the conversion from mode B could be limited by local structural
rearrangements of the side chains of residues that surround Ser373. Future modifications of
the inhibitors aim at retaining the interaction with the invariant Gln413, whereas the amino
acid divergence across PDEs is valuable for increasing the binding affinity and selectivity of
this novel class of PDE7 inhibitors.
Conclusions
Phosphodiesterase 7 is a high-affinity cAMP-specific PDE, the functional role of which in T-
cells has been the subject of some controversy. However, recent findings on tissue distribution
support the hypothesis that PDE7 could be a good target for the treatment of airway diseases,
T-cell related diseases, or even CNS disorders. Thus, the discovery of PDE7 inhibitors is
essential for the treatment of these disorders. The new heterocyclic compounds reported herein
are more potent than the previous quinazoline derivatives for the inhibition of PDE7. As a
result of their capability to inhibit PDE4, compounds 15, 19, 23, 25, 29, and 39 can be
considered as potential PDE7/PDE4 dual inhibitors for the treatment of T-cell disorders. The
derivatives 13, 26, and 40 show moderate in vitro cell toxicity similar to Rolipram or
BRL50481. Also thioxoquinazoline derivatives show a synergistic effect with Rolipram in
increasing intracellular levels of cAMP.
These compounds have remarkable anti-inflammatory activity, as shown by a significant
decrease in nitrite production in the murine macrophage cell line in response to the LPS
stimulation. Again, synergy between PDE4 and PDE7 inhibitors is observed. Moreover, the
in silico model predicts that the thioxoquinazolines are able to cross the BBB, further
emphasizing their potential biological use.
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Last of all, the structure of the PDE7A1–15 complex allows us to better understand the binding
site of this new family of PDE7 inhibitors, providing some important clues for the design of
new and selective inhibitors.
Overall, structural optimization on the thioxoquinazoline derivatives led to new compounds
with a very interesting profile as PDE7 or PDE7/PDE4 dual inhibitors that may be further
developed as new drugs for inflammatory and neurological diseases. Our hypothesis is based
on the fact that a decrease in cAMP levels promotes inflammation. Therefore, for diseases in
which PDEs are overexpressed or are overactive, PDE inhibitors will be useful as therapeutic
agents. This fact has been proven with PDE4 inhibitors for smooth-tissue diseases and COPD,
and it will be checked in the near future with PDE7 inhibitors for neurological disease, as PDE7
is widely expressed in the brain. Modulation of the inflammation process is without a doubt a
well-established neuroprotective strategy.
Experimental Section
Chemical procedures
Chemicals were purchased from commercial sources and used without further purification.
Melting points were measured by a Reichert–Jung Thermovar apparatus and were not
corrected. Flash column chromatography was carried out at medium pressure with silica gel
60 (E. Merck, particle size 0.040–0.063 mm, 230–240 mesh ASTM) and the indicated solvent
as eluent. Compounds were detected with UV light (254 nm). 1H NMR spectra were obtained
on the Bruker Avance 300 spectrometer working at 300 MHz. Typical spectral parameters:
spectral width 10 ppm, pulse width 9 µs (57°), data size 32 K. 13C NMR experiments were
carried out on a Bruker Avance 300 spectrometer operating at 75 MHz. The acquisition
parameters: spectral width 16 kHz, acquisition time 0.99 s, pulse width 9 µs (57°), data size
32 K. Chemical shifts are reported in ppm relative to internal Me4Si, and J values are reported
in Hz. IR spectra were recorded on a PerkinElmer Spectrum One spectrometer. EIMS data
were collected on an MSD 5973 instrument (Hewlett-Packard), and ESIMS data on an LC/
MSD Series 100 (Hewlett-Packard). Elemental analyses were performed by the analytical
department at CENQUIOR (CSIC), and the results obtained were within ±0.4% of the
theoretical values.
General procedure for the synthesis of thioxoquinazoline derivatives (6–13)—
The corresponding isothiocyanate derivative (1 equiv) at 0°C was added to a solution of the
commercially available 2-amino-5-bromobenzoic acid or 2-amino-3-methylbenzoic acid (1
equiv) in EtOH. The reaction mixture was stirred at 4°C during the time indicated in each case,
and the product was isolated by filtration. Sometimes a purification step was necessary. A
representative example (compound 6) is characterized below; full experimental details for
compounds 7–13 are given in the Supporting Information.
6-Bromo-4-oxo-3-phenyl-2-thioxo-1,2,3,4-tetrahydroquinazoline (6)—Reagents:
2-amino-5-bromobenzoic acid (0.80 g, 3.70 mmol), phenylisothiocyanate (0.4 mL, 3.70
mmol), EtOH (37.0 mL). Conditions: 3 days. Yield: 0.49 g (40%) as a white solid; mp: 326–
329°C (lit.[42] 322–325°C); 1H NMR (300 MHz, [D6]DMSO): δ = 13.22 (br s, 1H, NH), 8.09
(d, 1H, J = 2.1 Hz, H-5), 8.03 (dd, 1H, J = 8.7, 2.1 Hz, H-7), 7.50–7.37 (m, 4H, Ar-H, H-8),
7.35 ppm (d, 2H, J = 7.3 Hz, Ar-H); 13C NMR (75 MHz, [D6]DMSO): δ = 176.0 (C2), 158.7
(C4), 139.1 (Ar-C), 138.8 (C8a), 138.1 (C7), 129.2 (C5), 128.9 (2 C, Ar-C), 128.8 (2 C, Ar-
C), 128.1 (Ar-C), 118.2 (C8), 118.0 (C4a), 115.7 ppm (C6); IR (KBr): ν̃ = 3237, 3033, 1663,
1522, 1214 cm−1; MS (ESI) m/z 333, 335 [M+H]+, 355, 357 [M+Na]+; Anal. calcd for
C14H9BrN2OS: C 50.46, H 2.72, N 8.41, S 9.62, found: C 50.19, H 2.88, N 8.35, S 9.34.
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General procedure for the synthesis of 2-methylthio-4-oxo-3,4-
dihydroquinazoline derivatives (14–25)—Anhydrous K2CO3 (1 equiv) was added to a
solution of the corresponding 4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazoline derivative (1
equiv) in anhydrous DMF, and the mixture was stirred at RT for 1 h. To this solution, MeI (1.5
equiv) was added, and the reaction mixture was stirred at RT to completion. The solvent was
evaporated under reduced pressure. The residue was purified by using flash chromatography,
eluting with hexane/EtOAc in the proportions indicated. A representative example (compound
14) is characterized below; full experimental details for compounds 15–25 are given in the
Supporting Information.
2-Methylthio-4-oxo-3-phenyl-3,4-dihydroquinazoline (14)—Reagents: 4-oxo-3-
phenyl-2-thioxo-1,2,3,4-tetrahydroquinazoline (2)[29] (0.20 g, 0.78 mmol), K2CO3 (0.10 g,
0.78 mmol), DMF (16.9 mL), MeI (72.8 µL, 1.17 mmol). Conditions: 7 h. Purification: hexane/
EtOAc (5:1) as eluent. Yield: 0.15 g (76%) as a white solid; mp: 121–123°C (lit.[43] 124–126°
C); purity: 97% (by HPLC); 1H NMR (300 MHz, CDCl3 : δ = 8.15 (dd, 1H, J = 7.9, 1.3 Hz,
H-5), 7.63 (ddd, 1H, J = 8.0, 7.8, 1.3 Hz, H-7), 7.54 (d, 1H, J = 7.8 Hz, H-8), 7.49–7.42 (m,
3H, Ar-H), 7.29 (ddd, 1H, J = 8.0, 7.9, 1.0 Hz, H-6), 7.24–7.20 (m, 2H, Ar-H), 2.43 (s, 3H,
Me); 13C NMR (75 MHz, CDCl3): δ = 161.7 (C4), 157.8 (C2), 147.7 (C8a), 135.9 (Ar-C),
134.5 (C7), 129.8 (Ar-C), 129.5 (2 C, Ar-C), 129.0 (2 C, Ar-C), 127.1 (C5), 126.1 (C8), 125.6
(C6), 119.7 (C4a), 15.4 (Me); IR (KBr): ν̃ = 3070, 2929, 1700, 1595, 1264 cm−1; MS (ESI)
m/z 269 [M+H]+, 291 [M+Na]+, 559 [2M+Na]+, 560 [2M+Na+H]+; Anal. calcd for
C15H12N2OS: C 67.14, H 4.51, N 10.44, S 11.95, found: C 66.97, H 4.38, N 10.31, S 11.79.
General procedure for the synthesis of 2,4-dithioxo-1,2,3,4-
tetrahydroquinazoline derivatives (26–28)—2,4-bis(4-methoxyphenyl)-1,3,2,4-
dithiadiphosphetane-2,4-disulfide (Lawesson’s reagent; 1.5 equiv) was added to a solution of
the corresponding 4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazoline derivative (1 equiv) in
toluene, and the mixture was heated under reflux to completion. After cooling to RT, the solvent
was evaporated under reduced pressure. The residue was purified by using flash
chromatography, eluting with hexane/EtOAc in the proportions indicated. A representative
example (compound 26) is characterized below; full experimental details for compounds 27
and 28 are given in the Supporting Information.
3-Phenyl-2,4-dithioxo-1,2,3,4-tetrahydroquinazoline (26)—Reagents: 2[29] (75.0
mg, 0.29 mmol), Lawesson’s reagent (0.17 g, 0.44 mmol), toluene (6.4 mL). Conditions: 24
h. Purification: hexane/EtOAc (9:1) as eluent. Yield: 50.3 mg (63%) as an orange solid; mp:
253–256 °C (lit.[44] 252–254 °C); purity: 98% (by HPLC); 1H NMR (300 MHz, [D6]DMSO):
δ = 13.48 (br s, 1H, NH), 8.32 (dd, 1H, J = 8.2, 1.0 Hz, H-5), 7.78 (ddd, 1H, J = 8.3, 7.0, 1.0
Hz, H-7), 7.50–7.42 (m, 3H, Ar-H, H-6), 7.39–7.32 (m, 2H, Ar-H, H-8), 7.21 ppm (dd, 2H,
J = 8.3, 1.1 Hz, Ar-H); 13C NMR (75 MHz, [D6]DMSO): δ = 189.8 (C4), 172.8 (C2), 144.2
(Ar-C), 135.8 (C7), 135.2 (C8a), 131.7 (C5), 129.2 (2C, Ar-C), 128.5 (2C, Ar-C), 127.9 (Ar-
C), 125.2 (C8), 123.7 (C4a), 115.9 ppm (C6); IR (KBr): ν̃ = 3159, 3101, 3007, 2953, 1537,
1478, 1209 cm−1; MS (ESI) m/z 271 [M+H]+, 293 [M+Na]+; MS (EI) m/z 270 [M]+ (60); Anal.
calcd for C14H10N2S2: C 62.19, H 3.73, N 10.36, S 23.72, found: C 62.32, H 3.82, N 10.01, S
23.60.
General procedure for the synthesis of 2-methylthio-4-thioxo-3,4-
dihydroquinazoline derivatives (29–32)—2,4-bis(4-methoxyphenyl)-1,3,2,4-
dithiadiphosphetane-2,4-disulfide (Lawesson’s reagent; 1.5 equiv) was added to a solution of
the corresponding 2-methylthio-4-oxo-3,4-dihydroquinazoline derivative (1 equiv) in toluene,
and the mixture was heated under reflux to completion. After cooling to RT, the solvent was
evaporated under reduced pressure. The residue was purified by using flash chromatography,
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eluting with hexane/EtOAc in the proportions indicated. A representative example (compound
29) is characterized below; full experimental details for compounds 30–32 are given in the
Supporting Information.
2-Methylthio-3-phenyl-4-thioxo-3,4-dihydroquinazoline (29)—Reagents: 14 (75.0
mg, 0.27 mmol), Lawesson’s reagent (0.16 g, 0.41 mmol), toluene (6.1 mL). Conditions: 24
h. Purification: hexane/EtOAc (6:1) as eluent. Yield: 73.9 mg (93%) as a yellow solid, mp:
180–182 °C; purity: 98% (by HPLC); 1H NMR (300 MHz, CDCl3): δ = 8.68 (ddd, 1H, J =
8.2, 1.3, 0.3 Hz, H-5), 7.70 (ddd, 1H, J = 8.2, 6.9, 1.3 Hz, H-7), 7.59 (dd, 1H, J = 8.2, 0.9 Hz,
H-8), 7.56–7.51 (m, 3H, Ar-H), 7.37 (ddd, 1H, J = 8.2, 6.9, 0.9 Hz, H-6), 7.26–7.22 (m, 2H,
Ar-H), 2.49 ppm (s, 3H, Me); 13C NMR (75 MHz, CDCl3): δ = 189.9 (C4), 157.4 (C2), 142.8
(C8a), 140.4 (Ar-C), 134.8 (C7), 131.1 (C5), 129.9 (Ar-C), 129.8 (2C, Ar-C), 128.8 (2C, Ar-
C), 127.5 (C4a), 126.9 (C6), 126.8 (C8), 16.0 ppm (Me); IR (KBr): ν̃ = 3060, 2925, 1570, 1533,
1262, 1203 cm−1; MS (ESI) m/z 285 [M+H]+, 307 [M+Na]+, 591 [2M+Na]+; Anal. calcd for
C15H12N2S2 : C 63.35, H 4.25, N 9.85, S 22.55, found: C 63.58, H 4.76, N 9.83, S 22.30.
General procedure for the synthesis of 2-methylthio-4-oxo-3,4-dihydrothieno
[3,2-d]pyrimidine derivatives (35, 36)—Anhydrous K2CO3 (1 equiv) was added to a
solution of the corresponding 4-oxo-2-thioxo-1,2,3,4-tetrahydrothieno[3,2-d]pyrimidine
derivative (1 equiv) in anhydrous DMF, and the mixture was stirred at RT for 1 h. To this
solution, MeI (1.5 equiv) was added, and the reaction mixture was stirred at RT for 6 h. The
solvent was evaporated under reduced pressure. The residue was purified by using flash
chromatography, eluting with hexane/EtOAc (4:1).
2-Methylthio-4-oxo-3-phenyl-3,4-dihydrothieno[3,2-d]pyrimidine (35)—Reagents:
4-oxo-3-phenyl-2-thioxo-1,2,3,4-tetrahydrothieno-[3,2-d]pyrimidine (33)[29] (0.15 g, 0.57
mmol), K2CO3 (79.7 mg, 0.57 mmol), DMF (12.5 mL), MeI (53.8 µL, 0.86 mmol). Yield: 0.12
g (77%) as a white solid; mp: 188–190 °C; purity: > 99% (by HPLC); 1H NMR (300 MHz,
CDCl3): δ = 7.67 (d, 1H, J = 5.2 Hz, H-6), 7.50–7.44 (m, 3H, Ar-H), 7.27–7.22 (m, 2H, Ar-
H), 7.19 (d, 1H, J = 5.2 Hz, H-7), 2.42 ppm (s, 3H, Me); 13C NMR (75 MHz, CDCl3): δ =
160.2 (C2), 158.0 (C4), 156.5 (C7a), 135.6 (Ar-C), 134.4 (C6), 129.9 (Ar-C), 129.6 (2C, Ar-
C), 129.0 (2C, Ar-C), 124.4 (C7), 119.6 (C4a), 15.6 ppm (Me); IR (KBr): ν̃ = 3100, 3085,
2993, 1676, 1496, 1238 cm−1; MS (ESI) m/z 275 [M+H]+, 297 [M+Na]+, 589 [2M+Na
+NH4]+; Anal. calcd for C13H10N2OS2: C 56.91, H 3.67, N 10.21, S 23.37, found: C 56.67, H
3.89, N 10.06, S 23.11.
3-(2,6-Difluorophenyl)-2-methylthio-4-oxo-3,4-dihydrothieno-[3,2-d]pyrimidine
(36)—Reagents: 3-(2,6-difluorophenyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydrothieno[3,2-d]
pyrimidine (34)[29] (60.0 mg, 0.20 mmol), K2CO3 (28.0 mg, 0.20 mmol), DMF (4.4 mL), MeI
(18.9 µL, 0.30 mmol). Yield: 26.7 mg (43%) as a white solid; mp: 158–160°C; purity: 96%
(by HPLC); 1H NMR (300 MHz, CDCl3): δ = 7.81 (d, 1H, J = 5.2 Hz, H-6), 7.61–7.48 (m,
1H, Ar-H), 7.29 (d, 1H, J = 5.2 Hz, H-7), 7.15–7.09 (m, 2H, Ar-H), 2.56 ppm (s, 3H,
Me); 13C NMR (75 MHz, CDCl3): δ = 159.7 (C2), 159.0 (dd, 2C, J = 253.8, 3.5 Hz, Ar-C),
156.7 (C7a), 156.7 (C4), 134.9 (C6), 132.2 (t, 1C, J = 9.8 Hz, Ar-C), 124.6 (C7), 119.0 (C4a),
112.8 (t, 1C, J = 16.8 Hz, Ar-C), 112.4 (dd, 2C, J = 19.7, 3.3 Hz, Ar-C), 15.2 ppm (Me); IR
(KBr): ν̃ = 3072, 2923, 2853, 1684, 1503, 1237, 1009 cm−1; MS (EI) m/z 310 [M]+ (83); Anal.
calcd for C13H8F2N2OS2 : C 50.31, H 2.60, N 9.03, S 20.66, found: C 50.12, H 2.90, N 8.94,
S 20.37.
2-Methylthio-3-phenyl-4-thioxo-3,4-dihydrothieno[3,2-d]pyrimidine (37)—2,4-bis
(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide (Lawesson’s reagent; 0.15 g,
0.38 mmol) was added to a solution of 35 (70.0 mg, 0.25 mmol) in toluene (5.5 mL), and the
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mixture was heated under reflux for 24 h. After cooling to RT, the solvent was evaporated
under reduced pressure. The residue was purified by using flash chromatography, eluting with
hexane/EtOAc (5:1) to yield 63.3 mg (86%) of a yellow solid; 1H NMR (300 MHz, CDCl3):
δ = 7.82 (d, 1H, J = 5.4 Hz, H-6), 7.60–7.53 (m, 3H, Ar-H), 7.29–7.24 (m, 3H, Ar-H, H-7),
2.47 ppm (s, 3H, Me); 13C NMR (75 MHz, CDCl3): δ = 180.8 (C4), 160.5 (C2), 149.8 (C7a),
139.2 (Ar-C), 138.2 (C6), 134.9 (C4a), 130.2 (Ar-C), 129.8 (2C, Ar-C), 128.8 (2C, Ar-C),
124.6 (C7), 16.3 ppm (Me); MS (ESI) m/z 291 [M+H]+, 332 [M+Na+NH4+H]+.
3-(2,6-Difluorophenyl)-2-methylthio-4-oxo-3,4-dihydrobenzo-[4,5]thieno[3,2-d]
pyrimidine (39)—Anhydrous K2CO3 (59.9 mg, 0.43 mmol) was added to a solution of 3-
(2,6-difluorophenyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydrobenzo[4,5]thieno[3,2-d]pyrimidine
(38)[29] (0.15 g, 0.43 mmol) in anhydrous DMF (9.4 mL), and the mixture was stirred at RT
for 1 h. To this solution, MeI (40.5 µL, 0.65 mmol) was added, and the reaction mixture was
stirred at RT for 4 h. The solvent was evaporated under reduced pressure. The residue was
purified by using flash chromatography, eluting with hexane/EtOAc (5:1) to yield 0.14 g (92%)
of a white solid; mp: 183–185°C; 1H NMR (300 MHz, CDCl3): δ = 8.32 (d, 1H, J = 7.7 Hz,
H-9), 7.91 (d, 1H, J = 7.8 Hz, H-6), 7.63–7.50 (m, 3H, H-7, Ar-H, H-8), 7.16–7.11 (m, 2H,
Ar-H), 2.68 ppm (s, 3H, Me); 13C NMR (75 MHz, CDCl3): δ = 160.4 (C2), 158.8 (dd, 2C, J
= 254.0, 3.5 Hz, Ar-C), 157.2 (C4), 152.2 (C9b), 141.8 (C5a), 134.0 (C9a), 132.3 (t, 1C, J =
9,7 Hz, Ar-C), 129.0 (C7), 125.0 (C8), 123.7 (C9), 123.3 (C6), 118.5 (C4a), 112.8 (t, 1C, J =
16.8 Hz, Ar-C), 112.4 (dd, 2C, J = 19.7, 3.4 Hz, Ar-C), 15.3 ppm (Me); IR (KBr): ν̃ = 3066,
2925, 1697, 1530, 1497, 1478, 1243, 1013 cm−1; MS (ESI) m/z 361 [M+H]+, 383 [M+Na]+,
743 [2M+Na]+; Anal. calcd for (C13H8F2N2OS2) C 50.31, H 2.60, N 9.03, S 20.66; found: C
50.12, H 2.90, N 8.94, S 20.37; Anal. calcd for C17H10F2N2OS2 : C 56.65, H 2.80, N 7.77, S
17.79, found: C 56.75, H 3.02, N 7.46, S 17.69.
3-(2,6-Difluorophenyl)-2-methylthio-4-thioxo-3,4-dihydrobenzo-[4,5]thieno[3,2-
d]pyrimidine (40)—2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide
(Lawesson’s reagent; 0.12 g, 0.31 mmol) was added to a solution of 39 (75.0 mg, 0.20 mmol)
in toluene (4.5 mL), and the mixture was heated under reflux for 20 h. After cooling to RT, the
solvent was evaporated under reduced pressure. The residue was purified by using flash
chromatography, eluting with hexane/EtOAc (8:1) to yield 23.7 mg (30%) of a yellow solid;
mp: 250–252°C; 1H NMR (300 MHz, CDCl3): δ = 8.32 (dd, 1H, J = 7.8, 0.5 Hz, H-9), 7.88
(d, 1H, J = 8.0 Hz, H-6), 7.64–7.49 (m, 3H, H-7, Ar-H, H-8), 7.19–7.13 (m, 2H, Ar-H), 2.69
ppm (s, 3H, Me); 13C NMR (75 MHz, CDCl3): δ = 180.2 (C4), 161.0 (C2), 158.1 (dd, 2C, J =
254.4, 3.8 Hz, Ar-C), 145.7 (C9b), 143.5 (C5a), 134.1 (C9a), 132.6 (t, 1C, J = 9.7 Hz, Ar-C),
129.7 (C7), 125.3 (C8), 124.6 (C9), 123.1 (C6), 116.1 (C4a), 112.8 (Ar-C), 112.6 (dd, 2C, J =
19.2, 3.5 Hz, Ar-C), 15.9 ppm (Me); IR (KBr): ν̃ = 3065, 2922, 1539, 1473, 1247, 1012
cm−1; MS (ESI) m/z 377 [M+H]+, 399 [M+Na]+, 775 [2M+Na]+, 776 [2M+Na+H]+; Anal.
calcd for C17H10F2N2S3: C 54.24, H 2.68, N 7.44, S 25.55, found: C 54.19, H 3.01, N 7.49, S
25.45.
Subcloning, protein expression, and purification
The expression and purification of the catalytic domain of human PDE7A1 (residues 130–482)
has been previously described.[36] Briefly, the PDE7A1 was subcloned into vector pET-32a
and transferred into E. coli strain BL21 (codonplus). The E. coli culture carrying pET-PDE7A1
was grown in 2×YT medium at 37°C to absorption A600 = 1.0 and then 0.1 mM isopropyl-β-D-
thiogalactopyranoside was added for further growth at 15°C for 12–16 h. The catalytic domain
of PDE7A1 was passed through a Ni-NTA column (Qiagen), subjected to thrombin cleavage,
and further purified with Q-Sepharose (Amersham Biosciences) and Sephacryl S300
(Amersham Biosciences) columns. A typical batch of purification yielded ~5 mg PDE7A1
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from 4 L cell culture. Purified protein showed a single band in SDS-PAGE and native PAGE,
and is estimated to have > 95% purity.
Phosphodiesterase inhibition assay
The catalytic domain of PDE7A1 (130–482) and full-length PDE4D2 (1–507) were subcloned
into pET vectors, overexpressed in E. coli strain BL21, and purified to homogeneity, as
previously reported.[36] The enzymatic activities of PDE7A1 and PDE4D2 were assayed by
incubating the enzymes with 100 µL reaction mixture of 20 mM Tris·HCl (pH 7.5), 10 mM
MgCl2, 1mM DTT, and [3H]cAMP (20 000 cpm per assay, Sigma–Aldrich) at RT for 15 min.
The reactions were terminated by addition of 200 µL 0.2M ZnSO4 when 20–50% of cAMP was
hydrolyzed. The reaction product [3H]AMP was precipitated by addition of 200 µL 0.12M Ba
(OH)2 (Sigma–Aldrich), whereas unreacted [3H]cAMP remained in the supernatant.
Radioactivity of the supernatant was measured in liquid scintillation cocktail (ScintiSafe
Plus™ 30%, Fisher Scientific) with an LKB Rack-Beta 1214 counter. For measurement of
inhibition, six to eight different inhibitor concentrations were used with a substrate
concentration one tenth of the KM value, and the suitable enzyme concentration. Each
measurement was repeated twice. The IC50 values were defined as the compound concentration
that effects 50% inhibition of the enzyme activity.
Cell viability assays
The effect of PDE4, PDE7, and dual inhibitors on T-cell viability was determined by propidium
iodide (PI) cell staining assays using the murine T-cell line D10.G4.1. Cells (1 × 105) were
cultured in Click medium[45] in the presence of various concentrations of each inhibitor for
48 h. Samples were collected and washed twice in PBS before treatment with PI (5 µgmL−1)
in a final volume of 0.5 mL. Viable cells were identified by PI dye exclusion using a Becton
Dickinson FACs Canto flow cytometer. The number of events collected for each sample in
each series was the same (20000–50000).
cAMP measurements
D10.G4.1 cells were stimulated for 1 h with ionomycin and PMA in 96-well plates (5 × 104
cells per well), in the presence or absence of PDE inhibitors (200 µM) or vehicle (DMSO).
Intracellular cAMP was determined by a competitive enzyme immunoassay (EIA) system
(Amersham, GE Healthcare).
Nitrite production
Raw 264.7 cells in a 96-well plate were treated or untreated for 1 h with various PDE inhibitors
(10 µM) and then stimulated with 10 µg mL−1 of LPS for 24 h. The culture supernatants (50
µL) were transferred to a 96-well assay plate, mixed with 50 µL of Griess reagent, and
incubated for 15 min at RT. The absorbance (520 nm) of the mixture was measured on a
microplate reader.
Crystallization and structure determination
Crystals of PDE7A1–15 were grown by hanging drop at 4°C. The catalytic domain of 5 mg
mL−1 PDE7A1 (amino acids 130–482) in a storage buffer of 50 mM NaCl, 20 mM Tris·HCl (pH
7.5), 1 mM β-mercaptoethanol, and 1 mM EDTA was mixed with 1 mM 15. The protein drops
contained 2 µL PDE7A1–15 and 2 µL well buffer of 0.6–0.8M (NH4)2SO4, 2.5–5 mM β-
mercaptoethanol, 10 mM EDTA, 0.1M Tris·HCl, pH 7.5. Diffraction data were collected on
beamline X29 of the National Synchrotron Light Source (Table 5). The PDE7A1–15 crystal
had the space group P3121 with cell dimensions of a = b = 115.4, and c = 64.4 Å The diffraction
data were processed by the program HKL.[46] The structure of PDE7A1–15 was solved by
molecular replacement program AMoRe,[47] using PDE7A1-IBMX[36] as the initial model.
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The atomic model was rebuilt by program O[48] against the electron density map that was
improved by the density modification package of CCP4. The structure was refined by CNS.
[49]
The coordinates and structural factors have been deposited into the Protein Data Bank with the
accession code 3G3N.
Molecular modeling
Docking was performed with the program rDock, which is an extension of the program
RiboDock,[50] using an empirical scoring function calibrated on the basis of protein–ligand
complexes.[51] This program uses an empirical scoring function for attractive and repulsive
polar interactions in combination with a Lennard–Jones potential to define the van der Waals
term. Ligand internal energies used the same terms as the intermolecular potential, plus a
dihedral potential derived from the Tripos force field. A full search on ligand poses was
performed using a genetic algorithm, in which a conventional chromosome representation of
translation, rotation, and rotatable bond dihedral angles was used, while the receptor site was
kept fixed. The reliability of rDock was assessed by docking eight PDE4 inhibitors, which
were selected on the basis of their structural resemblance to the compounds (see Supporting
Information). Thus, all of them are neutral and possess at least two rings, which may or may
not be fused. Moreover, superposition of the X-ray crystallographic structures of the ligand–
PDE4 complexes confirmed unambiguously the structural similarity of the ligand binding sites.
Water molecules were removed from the coordinates, and the docking volume was defined as
the space within 10 Å of the ligands in the binding site. Before docking, the structure of the
ligands was built up and energy minimized at the MP2/6-31G* level using Gaussian 03.[52]
Each compound was subjected to 100 docking runs, and the output docking modes were
analyzed by visual inspection in conjunction with the docking scores.
MM/PBSA calculations were performed using the program AMBER.[53] The partial atomic
charges for the compounds were derived using the RESP protocol[54] by fitting to the
molecular electrostatic potential calculated at the HF/6-31G* level with Gaussian 03. Prior to
MM/PBSA calculations, the inhibitor and the side chains of those residues pertaining to the
binding site (see above) were energetically minimized. The electrostatic contribution (ΔGele)
to the total free energy of binding (ΔGbind) was determined using a dielectric constant of 80
for the aqueous environment, whereas values of 2 or 4 were considered for the ligand–receptor
complex. The electrostatic potentials were calculated using a grid spacing of 0.25 Å. The
interior of the solutes was defined as the volume inaccessible to a solvent probe sphere of radius
1.4 Å. The nonpolar contribution (ΔGSAS) of the free energy was calculated using a linear
dependence with the solvent-accessible surface (0.025 kcal mol−1Å2). The van der Waals
interaction energy between ligand and protein (ΔGvdW) was determined using the standard
formalism and parameters implemented in AMBER. The relative internal conformational
energy (ΔGint) of the receptor–ligand complexes was determined using the AMBER force field
and considered when comparing the two binding modes of the ligand. Finally, entropy changes
upon complex formation were assumed to be very similar in the two binding modes and
therefore would cancel out in the comparison of the relative binding affinities.
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Figure 1.
Toxicity induced in D10.G4.1 cells by the PDE inhibitors. Each inhibitor concentration (µM)
is indicated in parentheses. Propidium iodide (PI) cell staining was measured by flow
cytometry. Results are referenced to the value obtained for the control [without treatment with
PDE inhibitor (100 %)]. The experiments for each PDE inhibitor at three concentrations were
repeated at least twice; each value is shown as the mean ±SEM.
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Figure 2.
Intracellular cAMP levels in D10.G4.1 cells treated with the indicated PDE inhibitor (200
µM). Values are presented as fmol cAMP in 5 × 104 cells. Data from the competitive enzyme
immunoassay (EIA) system were exported to the GraphPad Prism software program to perform
statistical analysis. The unpaired t-test with Welch’s correction was used to analyze significant
differences between the cAMP amount in the samples. *:p < 0.05, **:p < 0.01.
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Figure 3.
Raw 264.7 cells were incubated for 24 h with lipopolysaccharide (LPS; 10 µg mL−1) in the
absence or presence of various PDE inhibitors (10 µM), and the production of nitrite was
evaluated by the Griess reaction. Cells were pretreated with inhibitors for 1 h before LPS
stimulation. Values represent the mean ±SD from two independent experiments. ***:p < 0.001
versus LPS-treated cells.
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Figure 4.
Structure of the PDE7A1 catalytic domain. a) Ribbon diagram of the PDE7A1 catalytic
domain. The red and purple balls represent zinc and magnesium ions, respectively. b) Binding
of 15 at the active site of PDE7A1. c) Electron density for 15. The (Fo−Fc) map was calculated
from the structure with omission of the inhibitor 15.
Castaño et al. Page 18
ChemMedChem. Author manuscript; available in PMC 2010 October 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5.
Superimposition of the residues in the binding site of PDE2A, PDE3A, PDE4A, PDE5,
PDE7A, PDE9, and PDE10A. For the sake of clarity, only those mutations that are not
conserved relative to the composition of residues in the binding site of PDE7A1 are shown. a)
Representation of the PDE7A1 binding site and of the nonconservative mutations with
compound 15 in the X-ray crystallographic binding mode B (gray). b) Alternative pose of 15
(blue) in the PDE7A1 binding site found in docking studies, which enables hydrogen bonding
with the invariant Gln413.
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Scheme 1.
Reagents and conditions: a) R″NCS, EtOH, 4°C.
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Scheme 2.
Reagents and conditions: a) MeI, K2CO3, DMF, RT; b) Lawesson’s reagent, toluene, Δ.
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Scheme 3.
Reagents and conditions: a) MeI, K2CO3, DMF, RT; b) Lawesson’s reagent, toluene, Δ.
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Scheme 4.
Reagents and conditions: a) MeI, K2CO3, DMF, RT; b) Lawesson’s reagent, toluene, Δ.
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Table 1
Inhibition of PDE7A and PDE4B.
Compd PDE7A PDE4B
1 8.0 19.0
2 5.5 21.7
3 5.5 37
4 48.5 13
5 1.9 56
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Table 2
Inhibition of PDE7A1 and PDE4D2.
IC50 [µM]
Compd PDE7A1 PDE4D2[a]
IBMX 8.1±0.4 31
Rolipram 129±10 0.55±0.05
6 >10 ND
7 >10 ND
8 >10 ND
9 ~10 ND
11 >1 ND
12 >10 ND
13 1.7±0.1 34±5
15 0.51±0.02 3.5±0.3
16 ~10 ND
18 >1 ND
19 0.24±0.03 4.5±0.1
20 2.1±0.1 ND
21 1.86±0.18 ND
22 ~1 ND
23 0.13±0.02 1.4±0.2
24 >1 ND
25 0.27±0.02 1.1±0.2
26 1.04±0.08 5.70±0.03
27 ~1 ND
28 >1 ND
29 0.84±0.01 8.0±1.2
30 0.1–1 ND
31 >1 ND
32 0.1–1 ND
35 ~10 ND
36 0.8±0.2 ND
39 0.41±0.03 1.6±0.4
40 0.1–1 ND
[a]
ND: not determined.
ChemMedChem. Author manuscript; available in PMC 2010 October 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Castaño et al. Page 26
Ta
bl
e 
3
D
iv
er
ge
nc
e 
in
 th
e 
bi
nd
in
g 
si
te
 re
si
du
es
 o
f p
ho
sp
ho
di
es
te
ra
se
s.
PD
E
7A
[a
]
PD
E
2A
PD
E
3B
PD
E
4D
PD
E
5A
PD
E
9A
PD
E
10
A
Ty
r2
11
Ty
r
Ty
r
Ty
r
Ty
r
Ph
e
Ty
r
Ile
32
3
Le
u
Le
u
M
et
Le
u
M
et
Le
u
Ile
36
3
Le
u
Ile
Le
u
Le
u
Ile
Le
u
A
sn
36
5
A
sp
G
ly
A
sn
A
la
A
sn
Se
r
Pr
o3
66
G
ln
Pr
o
Pr
o
Ile
G
lu
V
al
Se
r3
73
Th
r
H
is
Ty
r
G
ln
A
la
Th
r
Se
r3
77
A
la
Th
r
Th
r
A
la
V
al
A
la
V
al
38
0
Ile
Ile
Ile
V
al
Le
u
Ile
Ph
e3
84
Ph
e
Ph
e
Ph
e
Ph
e
Ty
r
Ph
e
Le
u4
01
M
et
Ph
e
M
et
–
Ph
e
M
et
Il
e4
12
Le
u
Le
u
Se
r
M
et
A
la
G
ly
Le
u4
20
Ile
Ile
Ile
Ile
V
al
V
al
[a
] P
D
E7
A
1 
re
si
du
es
 w
ith
 n
on
co
ns
er
va
tiv
e 
ch
an
ge
s a
re
 sh
ow
n 
in
 b
ol
d.
ChemMedChem. Author manuscript; available in PMC 2010 October 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Castaño et al. Page 27
Ta
bl
e 
4
M
M
/P
B
SA
 a
na
ly
si
s o
f t
he
 re
la
tiv
e 
bi
nd
in
g 
af
fin
iti
es
 [k
ca
l m
ol
−1
] o
f c
om
po
un
d 
15
 in
 th
e 
X
-r
ay
-li
ke
 b
in
di
ng
 m
od
e 
B
 a
nd
 th
e 
al
te
rn
at
iv
e 
po
se
 A
.[a
]
M
od
e
ΔG
el
e
ΔG
SA
S
ΔG
vd
W
ΔΔ
G
in
t
ΔΔ
G
bi
nd
A
lte
rn
at
iv
e
11
.0
 (ε
 =
 2
)
−1
.7
−3
9.
9
3.
5
−2
.7
(A
)
2.
6 
(ε 
= 
4)
X
-r
ay
-li
ke
10
.9
 (ε
 =
 2
)
−1
.8
−3
3.
5
0.
0
0.
0
(B
)
2.
6 
(ε 
= 
4)
[a
] P
os
es
 sh
ow
n 
in
 F
ig
ur
e 
5.
ChemMedChem. Author manuscript; available in PMC 2010 October 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Castaño et al. Page 28
Table 5
Statistics on diffraction data and structure refinement.
Data collection
Space group P3121
Unit cell [Å] a = 115.4, b = 115.4, c = 64.4
Resolution [Å] 2.4
Unique reflections 18572
Fold redundancy 19.2
Completeness [%] 94.8 (66.7)[a]
Average I/σ 7.1 (3.1)[a]
Rmerge 0.102 (0.28)[a]
Structure refinement
R 0.210
Rfree 0.245 (10 %)[b]
Resolution [Å] 3.0–2.4
Reflections 18071
Bond RMSD [Å] 0.006
Angle [°] 1.1
AverageB[Å2]:
  Protein 32.0 (2596)[c]
  Compound 15 39.0 (21)[c]
  Zn 32.9 (1)[c]
  Mg 45.7 (1)[c]
[a]
Values in parentheses are for the highest-resolution shell.
[b]
The percentage of reflections omitted for calculation of Rfree.
[c]
The number of atoms in the crystallographic asymmetric unit.
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